8-K: UroGen Pharma Q1 2026 Results: ZUSDURI Revenue Surges

UroGen Pharma reported strong Q1 2026 financial results, driven by a more than doubling of ZUSDURI revenue quarter-over-quarter, alongside steady growth for JELMYTO and pipeline advancements.

Summary

• UroGen Pharma announced its first quarter 2026 financial results, highlighting significant revenue growth.
• ZUSDURI generated $29.2 million in revenue, a 109% increase from the previous quarter, attributed to broader utilization following the permanent J Code effective January 1, 2026.
• JELMYTO achieved $21.7 million in revenue, marking a 7% year-over-year increase.
• Total revenue for Q1 2026 reached $51.0 million, a 152% increase compared to Q1 2025.
• Research and Development (R&D) expenses decreased to $15.6 million from $19.9 million in Q1 2025.
• Selling, General, and Administrative (SG&A) expenses increased to $51.5 million from $35.0 million in Q1 2025, primarily due to ZUSDURI commercial activities.
• The company reported a net loss of $23.6 million ($0.47 per share) for Q1 2026, an improvement from a net loss of $43.8 million ($0.92 per share) in Q1 2025.
• Cash, cash equivalents, and marketable securities stood at $140.3 million as of March 31, 2026.
• The company expects 2026 JELMYTO revenue between $97 million and $101 million and full-year operating expenses between $240 million and $250 million.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, with significant revenue acceleration for a key product and pipeline advancements, despite ongoing net losses typical for the industry.

Positives

• ZUSDURI revenue more than doubled quarter-over-quarter, reaching $29.2 million, driven by the permanent J Code effective January 1, 2026.
• JELMYTO revenue grew 7% year-over-year to $21.7 million.
• Total revenue increased by 152% year-over-year to $51.0 million in Q1 2026.
• Net loss improved significantly to $23.6 million in Q1 2026 from $43.8 million in Q1 2025.
• UGN-103 is on track for an NDA submission in the second half of 2026, with six-month durability data expected mid-2026.
• UGN-501 IND submission is planned for Q2 2026, with a Phase 1 trial initiation by year-end.
• Expanded debt facility with Pharmakon Advisors, providing $200 million at closing to refinance existing debt and provide additional capital.

Negatives

• SG&A expenses increased by $16.5 million year-over-year, primarily due to ZUSDURI commercialization efforts.
• The company reported a net loss of $23.6 million for the quarter.
• Total shareholders' deficit was $(124,253) thousand as of March 31, 2026.

Risks

• Potential safety and other complications related to UroGen's products.
• Risks associated with protecting intellectual property and patent applications.
• Challenges in maintaining regulatory approval and potential labeling limitations.
• Competition in the uro-oncology market and market acceptance of ZUSDURI versus alternative therapies.
• The potential for payors to delay, limit, or deny coverage for ZUSDURI.
• The data from the UTOPIA trial may not be sufficient to support approval of UGN-103.
• UroGen may not successfully develop and receive regulatory approval for other RTGel technology products.
• General macroeconomic and geopolitical conditions could impact UroGen's business and financial position.

Future Outlook

The company expects 2026 JELMYTO revenue to be in the range of $97 million to $101 million and full-year operating expenses to be between $240 million and $250 million. ZUSDURI revenue guidance is not provided for the full year due to its early commercial stage. UGN-103 is slated for an NDA submission in the second half of 2026, with potential FDA approval in 2027. UGN-501 is expected to have an IND submission in Q2 2026 and a Phase 1 trial initiation by year-end.

Management Comments

• "2026 is off to a strong start, with expanding usage of ZUSDURI (mitomycin) for intravesical solution and clear acceleration across key commercial indicators, including prescriber trial and adoption."
• "These trends reflect growing clinical confidence in ZUSDURI as a primary, non-surgical therapy for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC)."
• "The early launch momentum is now translating into meaningful revenue growth, providing early validation of our commercial model and reinforcing the blockbuster potential for ZUSDURI."
• "In parallel, we continue to advance our broader pipeline, including next generation products UGN-103 in LG-IR-NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma (LG-UTUC), as well as UGN-501, our investigational, potentially best-in-class, next-generation oncolytic virus."
• "With this momentum, we are well positioned to execute our long-term growth strategy and continue to expand our leadership position in uro-oncology."

Industry Context

StockSavvy.ai notes that UroGen Pharma's strong Q1 2026 performance, particularly the rapid growth of ZUSDURI, aligns with the trend of increasing adoption for novel treatments in uro-oncology. The company's focus on next-generation pipeline products like UGN-103 and UGN-501 demonstrates a strategic commitment to innovation within a competitive biotech landscape.

Comparison to Industry Standards

• The 109% quarter-over-quarter revenue growth for ZUSDURI is significantly above typical early-stage product launch benchmarks in the pharmaceutical industry, suggesting strong market penetration and acceptance.
• The 7% year-over-year growth for JELMYTO indicates sustained performance in a more mature market segment, which is generally in line with industry expectations for established therapies.
• The reported net loss of $23.6 million is common for clinical-stage and early commercial-stage biotech companies investing heavily in R&D and commercialization, and the improvement from the prior year is a positive sign.
• The company's cash position of $140.3 million provides a runway for continued operations and pipeline development, which is a critical metric for investors assessing financial stability in the sector.

Stakeholder Impact

• Shareholders: Positive impact from strong revenue growth and pipeline progress, potentially leading to increased valuation.
• Employees: Continued investment in commercial activities and R&D may lead to job growth and opportunities.
• Customers (Patients): Access to innovative treatments like ZUSDURI and JELMYTO for urothelial cancers.
• Healthcare Providers: Improved reimbursement clarity for ZUSDURI (via J Code) facilitates adoption and integration into practice.

Next Steps

• Host Key Opinion Leader (KOL) panel highlighting real-world experience with ZUSDURI at the American Urological Association (AUA) annual meeting on May 17th.
• Submit NDA for UGN-103 in the second half of 2026.
• Initiate Phase 1 clinical trial for UGN-501 by the end of 2026.
• Complete enrollment for the Phase 3 clinical trial of UGN-104 by the end of 2026.
• Submit IND for UGN-501 in the second quarter of 2026.

Key Dates

Recommendation

The significant acceleration in ZUSDURI revenue, driven by favorable reimbursement and strong clinical adoption, coupled with a robust pipeline and improved net loss, presents a compelling growth story. The company is executing well on its commercial strategy and advancing key pipeline assets, justifying a strong buy recommendation for investors seeking exposure to innovative oncology treatments.

Keywords

UroGen Pharma, ZUSDURI, JELMYTO, bladder cancer, urothelial cancer, Q1 2026, financial results, biotech